600062 China Resources Double-Crane Pharmaceutical
- 21.65
- -0.16-0.73%
China Resources Double-Crane Pharmaceutical News
China Resources Shuanghe (600062): The main business and Zizhu enterprises are waiting steadily for the layout of subsequent new fields
China Resources Shuanghe (600062): Performance is in line with expectations, product structure is continuously optimized
China Resources Shuanghe (600062): Steady growth in major infusion and specialty businesses promotes steady operation of the company
China Resources Shuanghe (600062): Transforming high-quality central enterprise chronic disease pharmaceutical platforms to enhance innovative value
China Resources Shuanghe (600062): 1Q24 performance is in line with expectations, specialty business achieves steady growth
China Resources Shuanghe (600062): Steady development of large infusions drives steady growth in the company's 2024Q1 performance
China Resources Shuanghe (600062): Another success, great results, and steady infusions/formulations
China Resources Shuanghe (600062): Performance slightly exceeded expectations, net profit margin further increased
China Resources Shuanghe (600062): Major infusions lead growth, and the layout of new fields can be expected
China Resources Shuanghe (600062): Proposed acquisition of China Resources Zizhu to specialize in the field of women's health
China Resources Shuanghe (600062): Building a Specialized Platform and Product Matrix to Further Strengthen Internationalization and Innovation Transformation
China Resources Shuanghe (600062): Zizhu Pharmaceutical launches extension to enhance women's health layout
China Resources Shuanghe (600062): China Resources Empowers Chemical Platform Companies Ready to Go
China Resources Shuanghe (600062): Big infusions are making great strides into the non-infusion sector and stabilizing
China Resources Shuanghe (600062): Major infusions speed up the recovery of specialty drugs for chronic diseases and the expected recovery
China Resources Shuanghe (600062) Annual Report Review: Collection Drags Down Pharmaceutical Profits and Accelerates New Product Development
China Resources Shuanghe (600062): Infusions are gradually recovering and the pharmaceutical sector stabilizes
China Resources Shuanghe (600062): Mining risks still exist when performance recovery takes place
China Resources Shuanghe (600062): Performance is stable but still facing great pressure to collect
China Resources Shuanghe (600062): Foreign Investment Rating (FIR)
Analysis
Price Target
No Data
No Data